The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Abstract
The beta‐site amyloid precursor protein cleaving enzyme‐1 (BACE‐1) initiates the generation of amyloid‐β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti‐Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states. The BACE‐1 inhibitor CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies. CNP520 reduced brain and cerebrospinal fluid (CSF) Aβ in rats and dogs, and Aβ plaque deposition in APP‐transgenic mice. Animal toxicology studies of CNP520 demonstrated sufficient safety margins, with no signs of hair depigmentation, retina degeneration, liver toxicity, or cardiovascular effects. In healthy adults ≥ 60 years old, treatment with CNP520 was safe and well tolerated and resulted in robust and dose‐dependent Aβ reduction in the cerebrospinal fluid. Thus, long‐term, pivotal studies with CNP520 have been initiated in the Generation Program. Alzheimer's disease (AD) is a chronic neurodegenerative disorder with increasing incidence in the aging societies, but without any disease‐modifying treatment. Deposition of toxic forms of the protein Aβ in the brain is pathologic. Treatment with a BACE‐1 inhibitor may prevent Aβ deposition. Alzheimer's disease (AD) is a chronic neurodegenerative disorder with increasing incidence in the aging societies, but without any disease‐modifying treatment. Deposition of toxic forms of the protein Aβ in the brain is pathologic. Treatment with a BACE‐1 inhibitor may prevent Aβ deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides LY2886721, many other candidates have also reached late stages of clinical trials, including atabecestat (Phase 2/3),305 elenbecestat (Phase 3),306 lanabecestat (Phase 2/3)307,308 and umibecestat (Phase 2/3).309 However, all of them have failed to receive final approval to reach the market.”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [309]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Umibecestat (14, CNP520), a fourth-generation BACE1 inhibitor, initially showed good safety and tolerability in early clinical studies.444,445”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [445]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to other BACE-1 inhibitors, CNP520 (umibecestat (labeled as 11, Figure 5)) has been shown to reduce the burden of amyloid-beta plaques in preclinical animals; it is presently undergoing testing phases [157,166,167].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [167]
In the citing paper
“or because of a cognitive worsening in the patients, as in the case of Umibecestat (Neumann et al., 2018)”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Neumann et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“…drugs that target Ab is therefore increasingly focused on treatment during the earlier stages of AD (the newly defined preclinical stage and during the stage of mild cognitive impairment) when the disease-modifying therapy targeting Ab presumably will be of greatest benefit (Selkoe & Hardy, 2016).”
BackgroundOn the size of the active site in proteases. I. Papain
Schechter, I., & Berger, A. (1967) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(67)80055-x · Cited by 5,204 · cited 1×
“BACE-1 shares high structural similarity with the catalytic and ligand binding sites of these enzymes; however, we increased selectivity for BACE-1 by exploiting the size differences of remote substrate binding pockets, in particular the extended S3 pocket (Schechter & Berger, 1967).”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“BACE-1 is a membrane-bound aspartyl protease required for the processing of the amyloid precursor protein (APP) to form the N-terminus of Ab peptides and the protein-soluble APPb (sAPPb) (Vassar et al, 1999).”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“CNP520 robustly reduces human CSF Ab In humans, determination of the direct BACE-1 product sAPPb and of Ab peptides in CSF allows measurement of the effect of CNP520 on APP processing in the brain (Blennow et al, 2010).”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 2×
“Inhibition of BACE-1 is a promising disease-modifying strategy for AD, validated by human genetics (Jonsson et al, 2012).”
BackgroundPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610 · cited 1×
“…with a biomarker signature for ongoing Ab deposition both in the APOE4 non-carrier and in the carrier group, but the proportion was higher in the carrier group, in line with reports documenting an increased risk of early Ab deposition in APOE4 carriers (Jansen et al, 2015; Hollands et al, 2017).”
ResultHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 1×
“…enrolls people at risk of developing AD based on age and genotype (presence of the APOE4 gene), we investigated the ability of CNP520 to inhibit Ab40 generation preclinically in the APOE4-TR mouse model, in which the mouse Apoe gene is replaced by the human APOE4 gene (Castellano et al, 2011).”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 10: e9316 | 2018 1 of 18 et al, 2018; Honig et al, 2018).”
MethodInfluentialLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833 · cited 1×
“Recent evidence that Ab deposition and measurable changes in brain biomarkers occur years before dementia symptoms appear suggests that in these trials, treatment was given too late during the course of the disease to be effective (Villemagne et al, 2011; Jack et al, 2013; Jones et al, 2016).”
BackgroundInflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782 · cited 1×
“In addition to toxic forms of Ab, the Abassociated neuroinflammatory processes are one of the key drivers of neuronal dysfunction and cognitive deficits in AD (Heneka & O’Banion, 2007).”
BackgroundThe Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725 · cited 1×
“One widely held hypothesis to explain this failure is that the intervention occurred too late during the course of the disease (Sperling et al, 2014).”
BackgroundControl of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703 · cited 1×
“…of myelin sheets, muscle spindle and proprioception changes due to decreased processing of neuregulin-1, and retina atrophy via impairment of vascular endothelial growth factor-1 cleavage-induced choroidal neovascularization (Willem et al, 2006; Cai et al, 2012; Cheret et al, 2013).”
BackgroundRandomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685 · cited 3×
“10 of 18 EMBO Molecular Medicine 10: e9316 | 2018 ª 2018 Novartis AG treatment with verubecestat reduces levels of soluble Ab forms, amyloid PET data indicate that deposited Ab is reduced only slightly over 18 months, probably because of slow physiological clearance (Egan et al, 2018).”
BackgroundResultInfluentialThree dimensions of the amyloid hypothesis: time, space and 'wingmen'
Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 662 · cited 1×
“…the subject of intense investigation in past decades, and a causal role for aggregated and deposited forms of amyloid-b (Ab) is supported by a vast body of histopathological, genetic, and biomarker studies (Jonsson et al, 2012; Potter et al, 2013; Musiek & Holtzman, 2015; Scheltens et al, 2016).”
BackgroundHuman amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599 · cited 1×
“The rate constant for clearance of Ab40 from human CSF was 0.068 0.002/ h, corresponding to a half-life of 10.2 h (Appendix Fig S3), close to previous estimations using a kinetic isotope labeling technique (Bateman et al, 2006; Patterson et al, 2015).”
MethodInfluentialTake five—BACE and the γ‐secretase quartet conduct Alzheimer's amyloid β‐peptide generation
Haass, C. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600061 · Cited by 550 · cited 1×
“Subsequent intramembrane proteolysis catalyzed by the c-secretase complex releases amyloid-b peptides of 38– 43 amino acids, which form the pathogenic oligomeric and fibrillary Ab species (Haass, 2004; Masters & Selkoe, 2012).”
BackgroundBiochemistry of Amyloid -Protein and Amyloid Deposits in Alzheimer Disease
Masters, C. L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006262 · Cited by 542 · cited 1×
“Subsequent intramembrane proteolysis catalyzed by the c-secretase complex releases amyloid-b peptides of 38– 43 amino acids, which form the pathogenic oligomeric and fibrillary Ab species (Haass, 2004; Masters & Selkoe, 2012).”
BackgroundCascading network failure across the Alzheimer’s disease spectrum
Jones, D. T., Knopman, D. S., Gunter, J. L., Graff-Radford, J., Vemuri, P., Boeve, B. F., Petersen, R. C., Weiner, M. W., & Jack, C. R. (2016) · Brain · doi:10.1093/brain/awv338 · Cited by 540 · cited 1×
“Recent evidence that Ab deposition and measurable changes in brain biomarkers occur years before dementia symptoms appear suggests that in these trials, treatment was given too late during the course of the disease to be effective (Villemagne et al, 2011; Jack et al, 2013; Jones et al, 2016).”
BackgroundCSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456 · cited 2×
“D Dose–CSF concentration profiles after 3 months of dosing (mean SEM, n = 22–24). ª 2018 Novartis AG EMBO Molecular Medicine 10: e9316 | 2018 9 of 18 elevated brain Ab (Janelidze et al, 2016; Pannee et al, 2016).”
BackgroundMethodBacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.018 · Cited by 435
Self-citationKennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N., Dockendorf, M. F., Egan, M., Ereshefsky, L., Hodgson, R. A., Hyde, L. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 428 · cited 3×
“Inhibition of BACE-1 by low-molecular-weight compounds has emerged as a new concept for treatment of AD (Vassar et al, 2014; Eketjall et al, 2016; Kennedy et al, 2016; Timmers et al, 2016, 2017; Yan et al, 2016; Cebers et al, 2017) by preventing the generation and deposition of Ab rather than just…”
BackgroundForecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States
Brookmeyer, R., Abdalla, N., Kawas, C. H., & Corrada, M. M. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.10.009 · Cited by 406
Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice
Dominguez, D., Tournoy, J., Hartmann, D., Huth, T., Cryns, K., Deforce, S., Serneels, L., Camacho, I. E., Marjaux, E., Craessaerts, K., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505249200 · Cited by 359 · cited 1×
“BACE-1 (B6,129T2-TgH(Bace1)1Goe) and BACE-2 (B6,129P2-TgH(Bace2) 1Leu) KO mice were received from the laboratory of B. De Strooper (Dominguez et al, 2005).”
MethodMay, P. C., Dean, R. A., Lowe, S. L., Martenyi, F., Sheehan, S. M., Boggs, L. N., Monk, S. A., Mathes, B. M., Mergott, D. J., Watson, B. M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3647-11.2011 · Cited by 336 · cited 3×
“The importance of sparing the BACE-1-related enzyme CatD has become obvious from the reports on retinal degeneration in the rat after treatment with the BACE inhibitors LY2811376 and AMG-8718 (May et al, 2011; Fielden et al, 2015).”
BackgroundVassar, R., Kuhn, P., Haass, C., Kennedy, M. E., Rajendran, L., Wong, P. C., & Lichtenthaler, S. F. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12715 · Cited by 311 · cited 1×
“Inhibition of BACE-1 by low-molecular-weight compounds has emerged as a new concept for treatment of AD (Vassar et al, 2014; Eketjall et al, 2016; Kennedy et al, 2016; Timmers et al, 2016, 2017; Yan et al, 2016; Cebers et al, 2017) by preventing the generation and deposition of Ab rather than just…”
BackgroundIncreased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236 · cited 1×
“…the subject of intense investigation in past decades, and a causal role for aggregated and deposited forms of amyloid-b (Ab) is supported by a vast body of histopathological, genetic, and biomarker studies (Jonsson et al, 2012; Potter et al, 2013; Musiek & Holtzman, 2015; Scheltens et al, 2016).”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“However, several trials in early to moderate stages of dementia have failed to meet their primary endpoints or were stopped at interim analysis (Mullane & Williams, 2013; Hawkes, 2017; Egan 1 Neuroscience, Novartis Institute for BioMedical Research, Basel, Switzerland 2 Translational Medicine,…”
BackgroundMay, P. C., Willis, B. A., Lowe, S. L., Dean, R. A., Monk, S. A., Cocke, P. J., Audia, J. E., Boggs, L. N., Borders, A. R., Brier, R. A., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4129-14.2015 · Cited by 206 · cited 1×
“However, limited selectivity for BACE-1 over cathepsin D (CatD), the off-target inhibition of which is a principal driver of ocular toxicity, and liver enzyme elevation have led to the termination of some early BACE-1 inhibitors in clinical trials (May et al, 2011, 2015; Zuhl et al, 2016).”
BackgroundAge and amyloid effects on human central nervous system amyloid‐beta kinetics
Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24454 · Cited by 200 · cited 1×
“The rate constant for clearance of Ab40 from human CSF was 0.068 0.002/ h, corresponding to a half-life of 10.2 h (Appendix Fig S3), close to previous estimations using a kinetic isotope labeling technique (Bateman et al, 2006; Patterson et al, 2015).”
MethodInfluentialPathogenic Mechanisms of Alzheimer's Disease Analyzed in the APP23 Transgenic Mouse Model
STURCHLER‐PIERRAT, C., & STAUFENBIEL, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06915.x · Cited by 168
Self-citationDesigning Drugs to Avoid Toxicity
Smith, G. F. (2011) · Progress in medicinal chemistry · doi:10.1016/b978-0-12-381290-2.00001-x · Cited by 137 · cited 1×
“Thus, in vivo metabolism of CNP520 forms an ortho-aminopyridine-containing metabolite with no known safety flag (Fig 1D) and does not generate aniline with its associated genotoxicity risk (Smith, 2011).”
BackgroundCai, J., Qi, X., Kociok, N., Skosyrski, S., Emilio, A., Ruan, Q., Han, S., Liu, L., Chen, Z., Bowes Rickman, C., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101084 · Cited by 136 · cited 1×
“…of myelin sheets, muscle spindle and proprioception changes due to decreased processing of neuregulin-1, and retina atrophy via impairment of vascular endothelial growth factor-1 cleavage-induced choroidal neovascularization (Willem et al, 2006; Cai et al, 2012; Cheret et al, 2013).”
BackgroundEketjäll, S., Janson, J., Kaspersson, K., Bogstedt, A., Jeppsson, F., Fälting, J., Haeberlein, S. B., Kugler, A. R., Alexander, R. C., & Cebers, G. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150834 · Cited by 132 · cited 1×
“Inhibition of BACE-1 by low-molecular-weight compounds has emerged as a new concept for treatment of AD (Vassar et al, 2014; Eketjall et al, 2016; Kennedy et al, 2016; Timmers et al, 2016, 2017; Yan et al, 2016; Cebers et al, 2017) by preventing the generation and deposition of Ab rather than just…”
BackgroundBACE inhibition-dependent repair of Alzheimer’s pathophysiology
Keskin, A. D., Kekuš, M., Adelsberger, H., Neumann, U., Shimshek, D. R., Song, B., Zott, B., Peng, T., Förstl, H., Staufenbiel, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708106114 · Cited by 125 · cited 1×
“…with NB-360, another oxazine BACE-1/2 inhibitor, in transgenic mice have shown beneficial effects on ADrelevant downstream markers tau and neurofilament light chain, as well as neuronal behavior restoring impaired brain connectivity (Bacioglu et al, 2016; Keskin et al, 2017; Schelle et al, 2017).”
BackgroundSelf-citationBace1 and Neuregulin‐1 cooperate to control formation and maintenance of muscle spindles
Cheret, C., Willem, M., Fricker, F. R., Wende, H., Wulf‐Goldenberg, A., Tahirovic, S., Nave, K., Saftig, P., Haass, C., Garratt, A. N., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.146 · Cited by 124
Neumann, U., Rueeger, H., Machauer, R., Veenstra, S. J., Lueoend, R. M., Tintelnot-Blomley, M., Laue, G., Beltz, K., Vogg, B., Schmid, P., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0033-8 · Cited by 113 · cited 4×
“Cellular Ab release assays were done in CHO cells stably transfected with human wild-type and human APP were done as described (Neumann et al, 2015).”
BackgroundMethodInfluentialSelf-citationSpecific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein
Ben Halima, S., Mishra, S., Raja, K. M. P., Willem, M., Baici, A., Simons, K., Brüstle, O., Koch, P., Haass, C., Caflisch, A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.076 · Cited by 105
Cebers, G., Alexander, R. C., Haeberlein, S. B., Han, D., Goldwater, R., Ereshefsky, L., Olsson, T., Ye, N., Rosen, L., Russell, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160701 · Cited by 91 · cited 2×
“…III trials), have a good selectivity for BACE-1 over CatD, they still exhibit undesirable characteristics: hair depigmentation in animal studies due to high BACE2 inhibition and strong P-glycoprotein (P-gp)-mediated efflux that limits brain penetration (Cebers et al, 2016; Kennedy et al, 2016).”
BackgroundPannee, J., Portelius, E., Minthon, L., Gobom, J., Andreasson, U., Zetterberg, H., Hansson, O., & Blennow, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13838 · Cited by 85 · cited 2×
“D Dose–CSF concentration profiles after 3 months of dosing (mean SEM, n = 22–24). ª 2018 Novartis AG EMBO Molecular Medicine 10: e9316 | 2018 9 of 18 elevated brain Ab (Janelidze et al, 2016; Pannee et al, 2016).”
BackgroundMethodZuhl, A. M., Nolan, C. E., Brodney, M. A., Niessen, S., Atchison, K., Houle, C., Karanian, D. A., Ambroise, C., Brulet, J. W., Beck, E. M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13042 · Cited by 73 · cited 2×
“However, limited selectivity for BACE-1 over cathepsin D (CatD), the off-target inhibition of which is a principal driver of ocular toxicity, and liver enzyme elevation have led to the termination of some early BACE-1 inhibitors in clinical trials (May et al, 2011, 2015; Zuhl et al, 2016).”
BackgroundInhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer’s disease
Yan, R., Fan, Q., Zhou, J., & Vassar, R. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.025 · Cited by 71 · cited 1×
“…compounds has emerged as a new concept for treatment of AD (Vassar et al, 2014; Eketjall et al, 2016; Kennedy et al, 2016; Timmers et al, 2016, 2017; Yan et al, 2016; Cebers et al, 2017) by preventing the generation and deposition of Ab rather than just treating the dementia symptoms.”
BackgroundMattsson, N., Rajendran, L., Zetterberg, H., Gustavsson, M., Andreasson, U., Olsson, M., Brinkmalm, G., Lundkvist, J., Jacobson, L. H., Perrot, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031084 · Cited by 70 · cited 1×
“To follow this up, we chose dog as a non-rodent model, since dog BACE-1 protein shows a high sequence identity to human BACE-1 (82.4%), and effects of BACE-1 inhibitors on Ab in dog CSF have been investigated (Mattsson et al, 2012).”
BackgroundInfluentialSelf-citationShimshek, D. R., Jacobson, L. H., Kolly, C., Zamurovic, N., Balavenkatraman, K. K., Morawiec, L., Kreutzer, R., Schelle, J., Jucker, M., Bertschi, B., et al. (2016) · Scientific Reports · doi:10.1038/srep21917 · Cited by 69 · cited 3×
“…has any effects on melanin synthesis and hair pigmentation, we dosed C57/BL6 mice with CNP520 for 8 weeks; NB-360, which inhibits BACE-1 and BACE-2 equipotently and leads to hair depigmentation in mice because of reduced PMEL-17 processing (Shimshek et al, 2016), was used as positive control.”
Self-citationBeckmann, N., Gérard, C., Abramowski, D., Cannet, C., & Staufenbiel, M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4936-10.2011 · Cited by 66 · cited 2×
“We examined the occurrence of CMH following treatment with CNP520 in APP23 mice, a transgenic strain that develops vascular Ab pathology and displays an increased incidence of age-related CMH after treatment with anti-Ab antibodies (Beckmann et al, 2011).”
BackgroundSelf-citationCrystal Structure of Human BACE2 in Complex with a Hydroxyethylamine Transition-state Inhibitor
Ostermann, N., Eder, J., Eidhoff, U., Zink, F., Hassiepen, U., Worpenberg, S., Maibaum, J., Simić, O., Hommel, U., & Gerhartz, B. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.10.027 · Cited by 63 · cited 1×
“BACE-2 is the closest evolutionary relative of BACE-1, with high structural similarity (Ostermann et al, 2006), and therefore a strong candidate for off-target effects (drug interaction with binding partners other than BACE-1).”
BackgroundBarão, S., Gärtner, A., Leyva-Díaz, E., Demyanenko, G., Munck, S., Vanhoutvin, T., Zhou, L., Schachner, M., López-Bendito, G., Maness, P. F., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.059 · Cited by 62 · cited 1×
“Therefore, it may inhibit BACE-1 in the endosome more than in the trans-Golgi network, where BACE-1 cleavage of physiological (non-APP) substrates occurs (Barao et al, 2015; Ben Halima et al, 2016).”
BackgroundTimmers, M., Van Broeck, B., Ramael, S., Slemmon, J., De Waepenaert, K., Russu, A., Bogert, J., Stieltjes, H., Shaw, L. M., Engelborghs, S., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.08.001 · Cited by 60 · cited 1×
“…by low-molecular-weight compounds has emerged as a new concept for treatment of AD (Vassar et al, 2014; Eketjall et al, 2016; Kennedy et al, 2016; Timmers et al, 2016, 2017; Yan et al, 2016; Cebers et al, 2017) by preventing the generation and deposition of Ab rather than just treating the…”
BackgroundMerck ends trial of potential Alzheimer’s drug verubecestat
Hawkes, N. (2017) · BMJ · doi:10.1136/bmj.j845 · Cited by 59 · cited 1×
“…in early to moderate stages of dementia have failed to meet their primary endpoints or were stopped at interim analysis (Mullane & Williams, 2013; Hawkes, 2017; Egan 1 Neuroscience, Novartis Institute for BioMedical Research, Basel, Switzerland 2 Translational Medicine, Novartis Institute for…”
BackgroundMacrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application
Lerchner, A. M., Machauer, R., Betschart, C., Veenstra, S. J., Rueeger, H., McCarthy, C., Tintelnot‐Blomley, M., Jaton, A.-L., Rabe, S., Desrayaud, S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.092 · Cited by 58 · cited 1×
“In a previous series of BACE-1 inhibitors, we discovered that weakly basic compounds show good passive membrane permeation (Lerchner et al, 2010).”
BackgroundSelf-citationStructure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors
Rueeger, H., Rondeau, J., McCarthy, C., Möbitz, H., Tintelnot‐Blomley, M., Neumann, U., & Desrayaud, S. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.038 · Cited by 45 · cited 5×
“MDR-1-MDCK cells were obtained from Prof. ª 2018 Novartis AG EMBO Molecular Medicine 10: e9316 | 2018 13 of 18 A. Berns, Netherlands Cancer Institute, Amsterdam NL, and bidirectional transport measurements were done as described (Rueeger et al, 2011).”
BackgroundMethodInfluentialSelf-citationMeredith, J. E., Thompson, L. A., Toyn, J. H., Marcin, L. R., Barten, D. M., Marcinkeviciene, J. A., Kopcho, L. M., Kim, Y. J., Lin, A., Guss, V. L., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138974 · Cited by 43 · cited 1×
“Net drug transport into the brain is determined by the balance between passive blood vessel membrane permeation and P-pg-mediated outward transport (Meredith et al, 2008).”
BackgroundRetinal Toxicity Induced by a Novel β-secretase Inhibitor in the Sprague-Dawley Rat
Fielden, M. R., Werner, J., Jamison, J. A., Coppi, A., Hickman, D., Dunn, R. T., Trueblood, E., Zhou, L., Afshari, C. A., & Lightfoot-Dunn, R. (2015) · Toxicologic Pathology · doi:10.1177/0192623314553804 · Cited by 42 · cited 1×
“The importance of sparing the BACE-1-related enzyme CatD has become obvious from the reports on retinal degeneration in the rat after treatment with the BACE inhibitors LY2811376 and AMG-8718 (May et al, 2011; Fielden et al, 2015).”
BackgroundSchelle, J., Häsler, L. M., Göpfert, J. C., Joos, T. O., Vanderstichele, H., Stoops, E., Mandelkow, E., Neumann, U., Shimshek, D. R., Staufenbiel, M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.005 · Cited by 40
Self-citationLopez Lopez, C., Caputo, A., Liu, F., Riviere, M. E., Rouzade-Dominguez, M.-L., Thomas, R. G., Langbaum, J. B., Lenz, R., Reiman, E. M., Graf, A., et al. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.37 · Cited by 36
Self-citationTimmers, M., Barão, S., Van Broeck, B., Tesseur, I., Slemmon, J., De Waepenaert, K., Bogert, J., Shaw, L. M., Engelborghs, S., Moechars, D., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160829 · Cited by 32 · cited 1×
“…by low-molecular-weight compounds has emerged as a new concept for treatment of AD (Vassar et al, 2014; Eketjall et al, 2016; Kennedy et al, 2016; Timmers et al, 2016, 2017; Yan et al, 2016; Cebers et al, 2017) by preventing the generation and deposition of Ab rather than just treating the…”
BackgroundBinding modes of hERG blockers: an unsolved mystery in the drug design arena
Kalyaanamoorthy, S., & Barakat, K. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1418319 · Cited by 29 · cited 1×
“In our assessment of CNP520 cardiovascular safety, we paid special attention to the human Ether-à-go-go-Related Gene (hERG) potassium channel in the heart, as it is an important potential off-target for aromatic compounds with a basic/amphiphilic structure (Kalyaanamoorthy & Barakat, 2017).”
BackgroundVillarreal, S., Zhao, F., Hyde, L. A., Holder, D., Forest, T., Sondey, M., Chen, X., Sur, C., Parker, E. M., & Kennedy, M. E. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170056 · Cited by 28 · cited 1×
“No CMH events were observed for the BACE inhibitors NB-360 and verubecestat in APP-transgenic mice (Beckmann et al, 2016; Villarreal et al, 2017).”
BackgroundBeckmann, N., Doelemeyer, A., Zurbruegg, S., Bigot, K., Theil, D. J., Frieauff, W., Kolly, C., Moulin, P., Neddermann, D., Kreutzer, R., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.05.009 · Cited by 27 · cited 1×
“No CMH events were observed for the BACE inhibitors NB-360 and verubecestat in APP-transgenic mice (Beckmann et al, 2016; Villarreal et al, 2017).”
BackgroundSelf-citationRapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors
Zhu, H., Young, M. B., Nantermet, P. G., Graham, S. L., Colussi, D. J., Lai, M., Pietrak, B., Price, E. A., Sankaranarayanan, S., Shi, X., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.005 · Cited by 20 · cited 1×
“The concept of BACE-1 inhibition for the treatment of AD has gained significant momentum since the identification of low-molecular-weight, highly potent and brain-penetrating compounds derived from a cyclic amidine core structure (Zhu et al, 2010), such as CNP520.”
BackgroundCebers, G., Lejeune, T., Attalla, B., Soderberg, M., Alexander, R. C., Budd Haeberlein, S., Kugler, A. R., Ingersoll, E. W., Platz, S., & Scott, C. W. (2016) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2016.119 · Cited by 20
Fratiglioni, L., Qiu, C., & Palmer, K. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.04.005 · Cited by 16
APOE ɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults
Hollands, S., Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Harrington, K., Porter, T., Snyder, P. J., Ames, D. J., Fowler, C. J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161019 · Cited by 11 · cited 1×
“…with a biomarker signature for ongoing Ab deposition both in the APOE4 non-carrier and in the carrier group, but the proportion was higher in the carrier group, in line with reports documenting an increased risk of early Ab deposition in APOE4 carriers (Jansen et al, 2015; Hollands et al, 2017).”
Result
Cited by
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“Besides LY2886721, many other candidates have also reached late stages of clinical trials, including atabecestat (Phase 2/3),(305) elenbecestat (Phase 3),(306) lanabecestat (Phase 2/ 3)(307,308) and umibecestat (Phase 2/3).(309) However, all of them have failed to receive final approval to reach the market.”
BackgroundJeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Metadata
- Authors
- Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., Rueeger, H., Tintelnot‐Blomley, M., Staufenbiel, M., Shimshek, D. R., Perrot, L., Frieauff, W., Dubost, V., Schiller, H., Vogg, B., Beltz, K., Avrameas, A., Kretz, S., Pezous, N., Rondeau, J., Beckmann, N., Hartmann, A., Vormfelde, S., David, O. J., Galli, B., Ramos, R., Graf, A., & Lopez Lopez, C.
- Affiliations
- Novartis (Switzerland) (CH)
- Corresponding author
- Neumann, Ulf
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2018-09-17
- Volume
- 10
- Issue
- 11
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC6220303
- OpenAlex
- W2890206141
- Cited by
- 177
- References
- 65
- Citations by year
- 2026: 7 · 2025: 23 · 2024: 34 · 2023: 20 · 2022: 24 · 2021: 23 · 2020: 23 · 2019: 19 · 2018: 3
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, other-oa)
- Minerva Access (University of Melbourne) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Novartis Pharma AG, Basel, Switzerland
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- BACE1 inhibitors, Alzheimer's disease, amyloid-beta, amyloid hypothesis, disease prevention, early Alzheimer's disease, cerebrospinal fluid amyloid-beta, APP transgenic mice, veterinary toxicology, drug safety, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Animals, Astrocytes, Brain, Cathepsin D, Cerebral Hemorrhage, Female, Humans, Inflammation, Male, Mice, Inbred C57BL, Mice, Transgenic, Oxazines, Hominidae, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Microglia, Amyloid Precursor Protein Secretases, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.